CAS: 2476-35-9; 5-Bromo-2-Methoxybenzoic Acid

上下游产品

CAS号25016-01-7 5-溴-2-甲氧基苯甲醛 | CAS号579-75-9 邻甲氧基苯甲酸 | CAS号7120-41-4 5-溴-2-甲氧基苯甲酸甲酯 | CAS号89-55-4 5-溴水杨酸 | CAS号77-78-1 硫酸二甲酯 | CAS号104-92-7 对溴苯甲醚 | CAS号124-38-9 二氧化碳 | CAS号69-72-7 水杨酸 | CAS号21702-84-1 2,4-二溴苯甲醚 | CAS号4068-76-2 5-溴水杨酸甲酯 | CAS号107410-07-1 2-甲氧基-5-苯基苯甲酸 | CAS号55082-33-2 5-溴-2-羟基二苯甲酮 | CAS号106-41-2 对溴苯酚 | CAS号95-56-7 2-溴苯酚 | CAS号303111-31-1 5-溴-2-甲氧基苯甲酰胺 | CAS号99-58-1 3-溴-4-甲氧基苯甲酸 | CAS号7120-41-4 5-溴-2-甲氧基苯甲酸甲酯 | CAS号13130-23-9 2-甲氧基-3,5-二溴苯甲酸 | CAS号773134-60-4 5-溴-2-甲氧基苯甲酸乙酯 | CAS号67657-90-3 5-溴-2-甲氧基-3-硝基苯甲酸甲酯

📜5-溴水杨酸置于水,Sodium Hydroxide体系中,用 水 用作溶剂,化学反应 3.75H,反应生成5-溴-2-甲氧基苯甲酸
参考文献:3',4',5'-三甲氧基黄酮类水杨酸酯衍生物作为潜在抗肿瘤药的设计,合成和初步生物学评估†
标题:3',4',5'-三甲氧基黄酮类水杨酸酯衍生物作为潜在抗肿瘤药的设计,合成和初步生物学评估†
摘要:根据药效团结合原理,设计,合成了一组新的3',4',5'-三甲氧基黄酮类水杨酸酯衍生物,并对其生物学活性进行了评估.细胞毒性评估表明,化合物10V对hct-116细胞显示出比5-Fu更高的效价.初步的生物学活性研究表明,化合物10V可以抑制hct-116细胞的集落形成和迁移.此外,Hoechst 33258染色测定法和流式细胞仪显示用化合物10V治疗诱导hct-116细胞的凋亡呈浓度依赖性,但对它们的细胞周期无影响.Wb分析表明,Hif-1α,微管蛋白,Hk-2和pfk可能是化合物10V的潜在药效团靶标.微管蛋白是化合物10V的潜在药物靶标,这是通过分析与微管蛋白复合的化合物10V的晶体结构来解释的.这些结果表明,化合物10V可能是有前途的抗肿瘤药物候选物,值得进一步优化和评估.
Doi:10.1039/c8Nj04533J

专利信息

专利号:WO-2011106986-A1
优先权日:2010-03-02
标题:Inhibitors of hepatitis c virus ns5b polymerase
发明人：MCCOMAS CASEY CAMERON; LIVERTON NIGEL J; SOLL RICHARD; LI PENG; PENG XUANJIA; WU HAO
权利人:MERCK SHARP & DOHME; MCCOMAS CASEY CAMERON; LIVERTON NIGEL J; SOLL RICHARD; LI PENG; PENG XUANJIA; WU HAO
摘要:Compounds of formula (I) that are used as hepatitis C virus (HCV) NS5B polymerase inhibitors, the synthesis of such compounds, and the use of such compounds for inhibiting HCV NS5B polymerase activity, for treating or preventing HCV infections and for inhibiting HCV viral replication and /or viral production in a cell-based system. Wherein Z, R 30 , R 40 , R 50 and R 60 of compounds of formula (I) are herein defined as in the description.

专利号:US-2012328569-A1
优先权日:2010-03-02
标题:Inhibitors of hepatitis c virus ns5b polymerase
发明人：MCCOMAS CASEY CAMERON; LIVERTON NIGEL J; SOLL RICHARD; LI PENG; PENG XUANJIA; WU HAO; NARJES FRANK; HABERMANN JOERG; KOCH UWE; LIU SHILAN
权利人:MCCOMAS CASEY CAMERON; LIVERTON NIGEL J; SOLL RICHARD; LI PENG; PENG XUANJIA; WU HAO; NARJES FRANK; HABERMANN JOERG; KOCH UWE; LIU SHILAN
摘要:Disclosed are compounds of formula (I) that are used as hepatitis C virus (HCV) NS5B polymerase inhibitors, the synthesis of such compounds, and the use of such compounds for inhibiting HCV NS5B polymerase activity, for treating or preventing HCV infections and for inhibiting HCV viral replication and/or viral production in a cell-based system.

专利号:US-11299484-B2
优先权日:2018-10-10
标 题 :Inhibiting fatty acid synthase (FASN)
发明人：MARTIN MATTHEW W; ZABLOCKI MARY-MARGARET; MENTE SCOT; DINSMORE CHRISTOPHER; WANG ZHONGGUO; ZHENG XIAOZHANG
权利人:FORMA THERAPEUTICS INC
摘要:The present disclosure is directed to inhibitors of FASN. The compounds can be useful in the treatment of disease or disorders associated with the inhibition of FASN. For instance, the disclosure is concerned with compounds and compositions for inhibition of FASN, methods of treating, preventing, or ameliorating diseases or disorders associated with the inhibition of FASN, and methods of synthesis of these compounds.